|1.||Ohlstein, E H: 3 articles (02/2001 - 11/2000)|
|2.||Ma, X L: 3 articles (02/2001 - 11/2000)|
|3.||Chen, J: 3 articles (02/2001 - 11/2000)|
|4.||Dowsett, M: 2 articles (04/2004 - 06/2000)|
|5.||Hendrix, S L: 2 articles (12/2001 - 01/2001)|
|6.||Christopher, T A: 2 articles (02/2001 - 11/2000)|
|7.||Gao, F: 2 articles (02/2001 - 11/2000)|
|8.||Lopez, B L: 2 articles (02/2001 - 11/2000)|
|9.||Gu, J L: 2 articles (11/2000 - 11/2000)|
|10.||Yue, T L: 2 articles (11/2000 - 11/2000)|
01/01/2001 - "Postmenopausal women were screened for potential inclusion in 2 multicenter, double-blind, placebo-controlled studies of 2 years' duration to evaluate the safety and efficacy of idoxifene in the prevention of osteoporosis. "
12/01/1998 - "Together with its cholesterol lowering effect and lack of uterotrophic activity, these data suggest that idoxifene may be effective in the prevention of osteoporosis and other postmenopausal diseases without producing unwanted estrogenic effects on the endometrium."
07/01/2002 - "New SERMs to treat and prevent breast cancer, osteoporosis, and cardiovascular disease are undergoing clinical development, including idoxifene, droloxifene, ospemifene, lasofoxifene, arzoxifene, and MDL 103,323."
01/01/2006 - "Other SERMs approved or under development for use against breast cancer or osteoporosis include toremifene, GW5638, GW7604 (the active metabolite of GW5638), idoxifene, lasofoxifene, arzoxifene, bazedoxifene, EM-800 and acolbifene (the active metabolite of EM-800). "
11/01/2000 - "Taken together, these results demonstrate that idoxifene is an endothelium-dependent vasodilator and exerts significant endothelial protective effects against TNF alpha- and ischemia-reperfusion-induced endothelial injury. "
02/01/2001 - "This study investigated whether idoxifene, a selective estrogen receptor modulator (SERM), exerted protective effects against ischemia-reperfusion-induced shock. "
02/01/2001 - "Taken together, these results demonstrated that idoxifene exerted estrogen-like, endothelial-protective, and antishock effects in ovariectomized rats, suggesting that SERMs have therapeutic potential in tissue injury resulting from ischemia-reperfusion."
|3.||Breast Neoplasms (Breast Cancer)
01/01/1997 - "Idoxifene is a more potent antioestrogen and is effective in patients with advanced breast cancer. "
06/01/2000 - "Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer."
02/01/2003 - "Idoxifene was both active and well tolerated in postmenopausal women with metastatic breast cancer. "
01/01/1998 - "Length increase of the side chain of idoxifene does not improve its antagonistic potency in breast-cancer cell lines."
01/01/1997 - "The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance."
06/01/2000 - "Idoxifene has an antiproliferative effect in ER-positive but not ER-negative breast cancers, and no significant effect on apoptosis in the short-term."
05/01/1995 - "Pharmacokinetics and biodistribution of radiolabelled idoxifene: prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy."
06/01/2000 - "The percentage of Ki67-positive cells fell from a mean 19.7 +/- 2.7% (SE) to 13.4 +/- 3.4% in idoxifene-treated ER-positive tumors (n = 30; P = 0.0043), but there was no significant effect in placebo-treated ER-positive tumors (n = 27). "
08/01/1999 - "Both anti-E2s inhibited cell proliferation and caused a significant 3-fold induction of apoptosis in E2 supported tumors after 1 week, which was maintained for 3 months with idoxifene (3.1 versus 0.48% compared to E2 controls) but decreased back to baseline in tumors treated with tamoxifen (0.69%). "
08/01/1999 - "Both idoxifene and tamoxifen significantly inhibited E2-dependent tumor growth, whereas cis-idoxifene had little effect. "
|1.||Selective Estrogen Receptor Modulators (SERM)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Heterologous Transplantation (Xenotransplantation)